Item 8.01 Other Events

On October 22, 2021 Regen BioPharma, Inc. (the "Company") settled convertible notes outstanding in the principal amounts of $29,836 and accrued interest on convertible notes outstanding of $26,227, by paying the Noteholder the amount of $43,529.30 in cash.

The settled convertible notes contained a default provision providing that in the event that the Company were to become delinquent in its reporting obligations under the Securities Exchange Act of 1934 after the six month anniversary of the applicable note the noteholder would be entitled to convert the outstanding principal balances and accrued interest into shares of the Company's common stock at 65% the lowest closing bid price during the delinquency period ("Default Conversion Price").

The Company has determined that the language utilized in the aforementioned provision may be interpreted as permitting the noteholder to convert the outstanding principal balances and accrued interest at the Default Conversion Price even in the event that such delinquency has been cured. Pursuant to such interpretation the noteholders may have been able to convert the outstanding balances over time into 855,584,615 shares of the Company's common stock having an aggregate value of $16,598,341 (valued at the closing price of the Company's common shares as of October 21, 2021) such conversions being permitted so long as any one such conversion would not result in the noteholder holding over 9.9% of the Company's common shares.

2

© Edgar Online, source Glimpses